What temozolomide dose should be used concurrently with whole‑brain radiotherapy in an adult with glioblastoma multiforme?

Temozolomide Dosing with Radiotherapy for Glioblastoma Multiforme

For adults with newly diagnosed glioblastoma multiforme receiving concurrent radiotherapy, temozolomide should be administered at 75 mg/m² daily throughout the entire radiotherapy course (42 days for standard fractionation), followed by maintenance temozolomide starting at 150 mg/m² for 5 days every 28 days for 6 cycles. 1

Important Clarification: Focal vs. Whole-Brain Radiotherapy

Whole-brain radiotherapy (WBRT) is NOT the standard of care for glioblastoma. The evidence and guidelines consistently support focal/partial-brain radiotherapy as the treatment paradigm 2. The standard approach delivers 60 Gy in 30 fractions (2 Gy per fraction) to the tumor bed or resection site with a 2-3 cm margin 3, 1.

• WBRT produces no survival advantage over focal radiotherapy and increases unnecessary radiation to normal brain tissue 2
• The concurrent temozolomide dose of 75 mg/m² daily was established with focal radiotherapy, not WBRT 4, 5

Standard Dosing Regimen for Concurrent Phase

During the 42-day concurrent radiotherapy phase:

• Temozolomide 75 mg/m² daily for all days of radiotherapy, including weekends 3, 1
• Continue up to 49 days if blood counts and toxicity remain acceptable 1
• No dose reductions are recommended during concurrent therapy; only interruptions or discontinuation for toxicity 1

Continuation Criteria During Concurrent Phase

Treatment should continue only when ALL of the following are met 1:

• Absolute neutrophil count ≥1.5 × 10⁹/L
• Platelet count ≥100 × 10⁹/L
• Non-hematologic toxicity ≤Grade 1 (except alopecia, nausea, vomiting)

Interruption and Discontinuation Thresholds

Interrupt temozolomide if: 1

• ANC ≥0.5 but <1.5 × 10⁹/L
• Platelets ≥10 but <100 × 10⁹/L
• Grade 2 non-hematologic toxicity

Discontinue temozolomide if: 1

• ANC <0.5 × 10⁹/L
• Platelets <10 × 10⁹/L
• Grade 3-4 non-hematologic toxicity

Maintenance Phase Dosing

Four weeks after completing radiotherapy: 1

• Cycle 1: 150 mg/m² daily for 5 consecutive days, then 23 days rest (28-day cycle)
• Cycles 2-6: Escalate to 200 mg/m² daily for 5 days if Cycle 1 toxicity was acceptable (Grade ≤2 non-hematologic toxicity, ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L) 1
• If dose not escalated at Cycle 2, do not escalate in subsequent cycles 1

Critical Supportive Care Requirement

Pneumocystis jirovecii pneumonia (PCP) prophylaxis is mandatory during concurrent temozolomide and radiotherapy, continuing until lymphocyte recovery to Grade ≤1 3, 1. This is essential because both temozolomide and corticosteroids cause significant immunosuppression 6.

Monitoring Requirements

• Weekly complete blood counts during concurrent phase 1
• Day 22 CBC (or within 48 hours) during maintenance cycles, then weekly until counts recover 1

Age-Specific Considerations

For elderly patients (≥60-70 years): 2, 3

• Hypofractionated radiotherapy (e.g., 40 Gy in 15 fractions) is appropriate and non-inferior to standard fractionation
• Temozolomide can be added to hypofractionated radiotherapy with demonstrated survival benefit 3
• MGMT promoter methylation status should guide treatment decisions in elderly patients with borderline performance status 3

Common Pitfalls to Avoid

• Do not reduce the 75 mg/m² dose during concurrent therapy—only interrupt or discontinue based on toxicity 1
• Do not use WBRT unless dealing with multifocal/multicentric disease (rare scenario where limited data exists) 7
• Do not forget PCP prophylaxis—herpes encephalitis and opportunistic infections are serious risks 6
• Minimize corticosteroid doses when possible, as combined immunosuppression with temozolomide increases infection risk 6

Evidence Basis

The landmark trial establishing this regimen demonstrated median survival of 14.6 months with radiotherapy plus temozolomide versus 12.1 months with radiotherapy alone (hazard ratio 0.63, p<0.001), with 2-year survival of 26.5% versus 10.4% 4, 5. This regimen, known as the Stupp protocol, remains the standard of care for adults with newly diagnosed glioblastoma in good general condition and age <70 years 3.